INTRODUCTION
============

Liver cancer, mainly hepatocellular carcinoma (HCC), is one of the leading causes of cancer-related death worldwide ([@b31-0060414]). It generally has a poor prognosis as it is often diagnosed at an advanced stage when treatment is not effective. Tremendous efforts have been made to decipher the molecular mechanisms of HCC, and gene expression profiling of human HCCs has been used to identify subgroups of patients according to etiological factors, early pre-neoplastic lesions, stages of the disease, rate of recurrence and survival ([@b11-0060414]; [@b21-0060414]; [@b35-0060414]; [@b44-0060414]). In human HCC, *MYC* is commonly amplified and associated with unfavorable prognosis ([@b1-0060414]). A higher expression level of MYC is associated with more advanced status of HCC ([@b7-0060414]). However, at which stage and to what extent Myc contributes to human HCC is still unclear. Recently, Myc has been suggested to be at the center of human liver tumor malignant conversion, on the basis of genome-wide gene expression profiling ([@b15-0060414]), but this conclusion still lacks experimental confirmation and thus an *in vivo* animal model is highly desired.

In the past decade, the zebrafish has become an increasingly popular experimental model for human diseases ([@b24-0060414]; [@b26-0060414]; [@b32-0060414]). We have demonstrated that the zebrafish and human liver tumors have molecular conservation at various levels, indicating the potential of zebrafish for modeling human liver cancer ([@b18-0060414]). Although several Myc transgenic mouse models for liver cancers have been reported ([@b21-0060414]), we envision that comparative studies of Myc tumors in an evolutionary distant model such as zebrafish should disclose highly conserved features and biomarkers of Myc tumors. Thus, in the present study, we have generated an inducible *Myc* transgenic zebrafish line and demonstrated that overexpression of Myc in the liver results in obvious liver tumors. Furthermore, by transcriptomic analyses, we found that the zebrafish *Myc* tumor model not only captured the human liver cancer signature but also showed high similarity with mouse *Myc*-induced liver tumor models. We also identified a short list of Myc targets that could be used to predict Myc-causing malignancies. Our analyses suggested that this transgenic zebrafish line could serve as a model for human liver tumors induced by over-activation of *MYC*.

RESULTS
=======

Generation of Tet-On inducible *Myc* transgenic zebrafish, *TO(Myc)*
--------------------------------------------------------------------

In order to investigate the role of *Myc* in liver tumorigenesis, a transgenic line, named *TO(Myc)*, was generated by introducing mouse *Myc* cDNA in a Tet-On vector under a liver-specific zebrafish *fabp10* promoter ([@b10-0060414]). By whole mount *in situ* hybridization, we confirmed that transgenic *Myc* expression was specifically induced in the liver after doxycycline (Dox) treatment ([Fig. 1A,B](#f1-0060414){ref-type="fig"}). To investigate the effect of *Myc* overexpression on liver growth, *TO(Myc)* fish were crossed with the LiPan line, which has red fluorescent protein (RFP) expression in the liver to facilitate observation of liver development ([@b17-0060414]). As shown in [Fig. 1D](#f1-0060414){ref-type="fig"}, overgrowth of the liver was apparent after 4 days of Dox (40 μg/ml) treatment starting from 3 dpf (days postfertilization), in comparison with that of untreated controls ([Fig. 1C](#f1-0060414){ref-type="fig"}). By using different concentrations of Dox, we observed a clear dose-dependent increase of the liver size in *TO(Myc)* embryos, as indicated by two-dimensional (2D) measurement ([Fig. 1E](#f1-0060414){ref-type="fig"}). By contrast, no obvious change was noted in the non-*TO(Myc)* siblings (M-D+) even under high dosage (40 μg/ml) of Dox treatment. Consistent with the observations, the dose-dependent induction of *Myc* transgene expression was also confirmed by reverse transcription polymerase chain reaction (RT-PCR), in which the transgenic embryos were treated with increasing concentrations of Dox (10, 30 and 60 μg/ml) for 2 days from 2 dpf ([Fig. 1F](#f1-0060414){ref-type="fig"}). Although there was a dosage-dependent increase of proliferation in the *TO(Myc)* livers after Dox induction, there was no detectable apoptosis in the *TO(Myc)* livers at all concentrations of Dox from 10-60 μg/ml (data not shown).

![**Inducible *Myc* expression and liver overgrowth in *TO(Myc)* fry.** (A,B) Liver-specific *Myc* expression in *TO(Myc)* fry. *Myc* transgenic fry were treated with 10 μg/ml Dox from 2 dpf for two days and liver-specific *Myc* expression was confirmed by whole mount *in situ* hybridization at 4 dpf, as indicated by a yellow arrow. An untreated control is shown in A. (C,D) *In vivo* detection of liver overgrowth in *TO(Myc)* fry. Double transgenic fry from a cross of *TO(Myc)* and LiPan zebrafish were treated with 40 μg/ml Dox and livers were observed by RFP expression (D). An untreated control is shown in C. (E) Dose-dependent growth of liver in *TO(Myc)* fry. *TO(Myc)*/LiPan double transgenic fry were treated with increasing concentrations of Dox; liver imaging is shown in the pictures on the right. 2D measurement of liver areas were performed using ImageJ as described previously ([@b13-0060414]) and the quantitative data are shown on the left. The groups significantly different from the control group (M+D-) by Student\'s *t*-test are indicated: \**P*\<0.05; \*\**P*\<0.01. (F) Dose-dependent induction of *Myc* mRNAs in adult livers as detected by RT-PCR. Concentrations of Dox are indicated at top of each lane. M+, *TO(Myc)* fish; M-, non-transgenic siblings; D+, presence of doxycycline; D-, absence of doxycycline. *B-actin* transcripts served as loading controls for RT-PCR.](DMM010462F1){#f1-0060414}

###### TRANSLATIONAL IMPACT

**Clinical issue**

Liver cancer is a prominent malignancy, causing more than half a million deaths worldwide every year. Human liver tumors are morphologically and genetically heterogeneous, and the molecular pathogenesis of the disease is highly complex. Transgenic animals with altered expression of key oncogenes provide a tractable system to facilitate the understanding of the complex mechanisms of carcinogenesis. In addition, comparing liver tumors from evolutionarily distinct species, such as fish and human, should help identify more robust and reliable molecular pathways, as well as diagnostic and prognostic biomarkers, for liver cancer.

**Results**

The authors established an inducible liver cancer model by generating a transgenic zebrafish line in which the mouse *Myc* oncogene was inducibly expressed in the liver by tetracycline treatment \[*TO(Myc)* zebrafish\]. They observed a dosage-dependent induction of Myc expression with increasing concentrations of doxycycline (a tetracycline derivative), and high levels of Myc expression eventually caused liver tumors in 100% of transgenic zebrafish. Tumors progressed from hepatocellular adenoma to carcinoma with prolonged Myc induction. Cross-species analyses showed that the zebrafish *TO(Myc)* model correlated well with *Myc* transgenic mouse models of liver cancers at the transcriptome level. In addition, the authors found that *Myc*-induced zebrafish liver tumors have molecular signatures that are highly similar to that of human hepatocellular carcinoma. Finally, the authors found that a small subset of 16 Myc target genes could distinguish advanced human hepatocellular carcinoma from low-grade liver tumors.

**Implications and future directions**

These studies involving a *TO(Myc)* transgenic zebrafish model demonstrate the conserved role of Myc in promoting hepatocarcinogenesis in multiple vertebrate species. The identification of a small subset of Myc target genes might help to establish better prognostic markers for Myc-induced liver tumours.

Induction of liver tumors in *TO(Myc)*
--------------------------------------

To examine the tumorigenic potency of the *TO(Myc)* line, *TO(Myc)* transgenic zebrafish and their non-transgenic siblings were treated with Dox (60 μg/ml) from 21 dpf. All Dox-treated transgenic fish (M+D+) showed enlarged abdomens ([Fig. 2D](#f2-0060414){ref-type="fig"}) and obvious liver overgrowth ([Fig. 2E](#f2-0060414){ref-type="fig"}) after only 2-3 weeks of Dox induction (100%, *n*=50) compared to Dox-treated non-transgenic siblings (M-D+) ([Fig. 2A,B](#f2-0060414){ref-type="fig"}). Histological analysis of the M+D+ fish showed hyperplasia (HP; 6/10), mixed hyperplasia/ hepatocellular adenoma (HP/HCA; 1/10) and adenoma (3/10) ([Fig. 2F](#f2-0060414){ref-type="fig"}; [Table 1](#t1-0060414){ref-type="table"}). In general, the entire liver was uniformly transformed into tumor phenotype without the existence of normal liver tissue. For observation of the effect of prolonged activation of *Myc*, we treated the fish continuously for up to 16 weeks. The treated fish (M+D+) did not show significant increase in mortality ([Fig. 2M](#f2-0060414){ref-type="fig"}), but they did show more prominent liver enlargement ([Fig. 2J,K](#f2-0060414){ref-type="fig"}) and significantly smaller body size ([Fig. 2J,N](#f2-0060414){ref-type="fig"}) than control fish. Hematoxylin and eosin (H&E) examination of samples from 8 and 16 weeks post-treatment (wpt) revealed a progression of liver tumors from predominantly hyperplasia to adenoma ([Table 1](#t1-0060414){ref-type="table"}). We also noticed one case of early HCC, as shown in [Fig. 2L](#f2-0060414){ref-type="fig"}, confirming the liver tumor progression with prolonged *Myc* activation.

![**Induction of liver tumors in *TO(Myc)* fish.** (A-L) Transgenic and non-transgenic fish were treated with Dox (60 μg/ml) starting from 21 dpf and sampled at different times. Samples were collected at 3 wpt (A-F) and 16 wpt (G-L). The left column displays external appearance, the middle column shows internal abdominal organs with the livers outlined, and the right column depicts H&E staining of liver sections. At 3 wpt, non-transgenic siblings had normal body shape (A), whereas transgenic fish showed an enlarged belly (D). Dissection of a transgenic fish (E) showed an enlarged abdomen compared to a non-transgenic sibling (B). At 16 wpt, more obviously enlarged abdomen (J) and fully grown liver tumor (K) were observed, in comparison with the controls (G,H). Histological examination confirmed that most transgenic fish developed hyperplasia (F) at 3 wpt and adenoma (L) at 16 wpt in comparison with normal liver histology in non-transgenic siblings (C,I). (M,N) Survival curves (M) and body lengths (N) for the four experimental groups until 16 wpt. Noted body length was significantly different from the control group after just 2 weeks of treatment; \**P*\<0.0001. li, liver; in, intestine; sb, swimbladder. Scale bars: 2 mm, 1 mm and 100 μm for the left, middle and right columns, respectively.](DMM010462F2){#f2-0060414}

###### 

Progression of Myc-induced liver tumor

![](DMM010462T1)

RNA sequencing of *Myc*-induced liver tumors indicated a distinct transcriptomic pattern from control livers
------------------------------------------------------------------------------------------------------------

In order to investigate the molecular mechanism of *Myc*-induced liver tumors, livers from all four groups (transgenic and non-transgenic fish, treated or untreated with Dox) were collected after 4 months of Dox-treatment at 60 μg/ml. Two biological replicates (each with four or five pooled livers) were included for each group. About 40 million tags were sequenced for each sample mapped to the zebrafish RefSeq database for quantitative analysis of transcript expression ([supplementary material Table S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010462/-/DC1)). To verify the dynamic range of gene expression, reverse-transcription quantitative PCR (RT-qPCR) was performed for several selected genes with a range of 249,696 to 0.12 TPM (transcripts per million) in the control sample 1 (M-D-\_1). As shown in [Fig. 3A](#f3-0060414){ref-type="fig"}, there was a good correlation of the RNA sequencing data and RT-qPCR results.

![**Validation and characterization of RNA sequence tags.** (A) qPCR validation of RNA-SAGE results using untreated wild-type samples. The blue bars represent normalized ΔCp values from the qPCR results, and the red bars are logarithm-transformed (base 2) TPM values. Both ΔCp and TPM values are normalized against the ΔCp and TPM of bactin. (B) Hierarchial clustering of the eight samples. (C) Volcano plot showing the distribution of transcripts over different fold changes and *P*-values between control and tumor samples. The top ten up- and downregulated transcripts, ranked by their distance to the base point, are marked in red.](DMM010462F3){#f3-0060414}

To compare the molecular similarity of the tumor and control samples, whole transcriptomic data from all eight samples were subjected to hierarchical clustering using MeV software ([@b38-0060414]; [@b37-0060414]). As shown in [Fig. 3B](#f3-0060414){ref-type="fig"}, the two tumor samples (M+D+) were clustered as an independent branch and were well separated from all control samples (M-D-, M-D+ and M+D-), suggesting that there were substantial changes in the tumor transcriptome.

Differentially expressed genes in *Myc*-induced liver cancer
------------------------------------------------------------

In order to identify the genes important for liver cell transformation, a *t*-test was performed between the six control and two tumor samples. Differentially expressed genes were selected by accepting a *P*-value of \<0.05 and fold change \>1.5 for further analyses. In order to focus on physiologically relevant genes, we also set an expression level cutoff at an average of 10 TPM in either control or tumor samples, which is equivalent to about three transcripts per cell, based on an estimation of 300,000 transcripts per cell ([@b28-0060414]). Finally, 148 up- and 353 downregulated transcript entries were selected using these criteria ([supplementary material Tables S2, S3](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010462/-/DC1)). These up- and downregulated zebrafish genes were subsequently mapped to 125 and 207 human gene symbols. As illustrated in the volcano plot ([Fig. 3C](#f3-0060414){ref-type="fig"}), there were fewer upregulated genes than downregulated genes, but the upregulated genes were more deregulated as judged by their distances from the base point.

To understand the composition of these differentially expressed genes, Gene Ontology Slim classification analysis was performed ([Fig. 4A-C](#f4-0060414){ref-type="fig"}). Interestingly, all genes in the macromolecular complex and ribosome groups were upregulated ([Fig. 4B](#f4-0060414){ref-type="fig"}). By contrast, more genes involved in nucleotide binding, ion binding, protein binding, transferase activity, hydrolase activity, transporter activity, membrane and nucleus were downregulated. It is also interesting to note that there were more uncharacterized genes in the downregulated group than the upregulated group, probably implying that less attention was devoted to the downregulated genes in the *Myc* pathway and cancers in previous studies.

![**Functional classification and visualization of differentially expressed genes.** (A-C) Gene Ontology Slim classification of the up- and downregulated genes in *Myc*-induced liver tumors. Red and green bars represent up- and downregulated genes, respectively, in the three categories: biological process (A), cellular component (B) and molecular function (C). Numbers of genes are indicated at the top. (D) Heat map of ribosomal protein mRNA expression profiles. The eight individual samples are indicated at the top of each column and the gene names of ribosomal proteins are given on the right. Red and green represent up- and downregulation as indicated in the bar below. The numbers were calculated by dividing the TPM in one sample by the average TPM of the same transcripts across all eight samples.](DMM010462F4){#f4-0060414}

To gain more detailed functional insights into the differentially expressed gene list, gene ontology enrichment analysis was conducted. As shown in [Table 2](#t2-0060414){ref-type="table"}, ribosome and translation are the most prominent groups in the upregulation division. Consistent with this, all of the 59 ribosomal protein genes identified showed upregulation in the tumors ([Fig. 4D](#f4-0060414){ref-type="fig"}). Of these, 34 genes (*rpl4*/*5a*/*7a*/*8*/*9*/*10a*/*11*/*12*/*13*/*13a*/*18a*/*19*/*21*/*22*/*26*/*27a*/*34*/*36*/*36a* and rps*3*/*5*/*7*/*8*/*11*/*12*/*13*/*14*/*15*/*16*/*20*/*21*/*23*/*25*/*29*) and several major translation factors (*eif2s1*/*3*, *eif3c*/*d*/*ea*/*ha*, *eef1g* and *ef1a*) were present in the significantly upregulated group in the tumors ([supplementary material Table S2](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010462/-/DC1)).

###### 

Gene Ontology enrichment analysis of differentially expressed genes in *Myc*-induced zebrafish liver tumors

![](DMM010462T2)

We also compared the expression of endogenous myc genes. Out of the six members of the myc gene family in zebrafish (*myca, mycb, mych, mycl1a, mycl1b* and *mycn*), only *mycb* and *mych* were relatively highly expressed in the liver, with averages of 54.9 and 13.3 TPM, respectively, in the control samples (M-D-, M-D+ and M+D-) although these decreased to 13.3 and 3.5 TPM, respectively, in the liver tumor samples (M+D+). Thus, it seems that high level of transgenic expression of the mouse Myc negatively affects the expression of endogenous myc genes. By contrast, all the rest of the myc genes had extremely low expression level (0.0 to 2.3 TPM) in all the liver samples (control and tumor). Thus, it is impossible to evaluate their change during tumorigenesis.

*Myc* zebrafish model shows good correlation with *Myc*-induced mouse transgenic model
--------------------------------------------------------------------------------------

We next examined the similarity of *Myc* zebrafish model to various mouse HCC models, including two chemically induced \[ciprofibrate (CIP) and diethylnitrosamine (DENA)\], four transgenic (overexpression of *Myc*, *E2f1*, *Myc*/*E2f* or *Myc*/*Tgfa* in the liver) and one knockout (*Acox1*^−/−^) models ([@b21-0060414]). Hierarchical clustering analysis of gene expression patterns was used to assess the relative similarities between different mouse HCC models. Three distinctive HCC clusters were identified. Our *Myc* overexpression-induced liver cancer clearly distinguished the *Myc*-*E2f1*-*Myc*/*E2f1* cluster from the other models, and it showed the highest relatedness to *Myc*/*E2f1* transgenic mice, suggesting conservation of *Myc* signatures between zebrafish and mice liver tumors induced by overexpression of *Myc* ([Fig. 5A](#f5-0060414){ref-type="fig"}; [supplementary material Table S4](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010462/-/DC1)). Thus, our zebrafish model successfully resembles mouse liver tumor under similar a inducer (here *Myc*) and confirmed conservation between zebrafish and mouse liver cancers.

![**Comparison of*Myc*-induced zebrafish liver tumors with different stages of human HCC and seven mouse HCC models.** (A) Comparison of *Myc*-induced zebrafish liver cancer with seven mouse models. Hierarchical clustering of the seven mouse models were adapted from a previous publication ([@b21-0060414]). The level of similarity of *Myc*-induced zebrafish liver cancer and different mouse models are shown in different colors, with red indicating positive correlation and green indicating negative correlation. (B) Heat map showing expression patterns of 125 Myc upregulated genes (top) and 16 target genes (bottom) in different human conditions. The scale bar represents up- (red) or down- (blue) regulation of genes with fold change in log2 ratio.](DMM010462F5){#f5-0060414}

*Myc*-induced zebrafish liver tumors show the highest transcriptome similarity to HCC
-------------------------------------------------------------------------------------

Hepatocarcinogenesis is a multistage process following a dysplasia-adenoma-carcinoma sequence with distinct morphological and molecular signatures. Therefore, we compared the transcriptome of *Myc*-induced zebrafish liver tumors with those from different stages of human liver conditions: low grade dysplastic nodules (LGDN), high grade dysplastic nodules (HGDN), and very early, early, advanced and very advanced hepatocellular carcinoma (veHCC, eHCC, aHCC and vaHCC) ([Table 3](#t3-0060414){ref-type="table"}). In the first human HCC dataset (GSE12443) ([@b15-0060414]), the upregulated genes of *Myc*-induced zebrafish tumors clearly distinguished HGDN and eHCCs from others, and they showed significant similarity to eHCC. Another human HCC dataset (GSE6764) included more advanced HCC stages, in which the pathological HCC stages were defined by tumor size, differentiation status and metastasis level ([@b44-0060414]). Similarly, the upregulated genes of the zebrafish tumors successfully captured human HCC but not the less severe groups including HCA ([Fig. 5B](#f5-0060414){ref-type="fig"}; [Table 3](#t3-0060414){ref-type="table"}). Within the HCC group, it showed the highest similarity with very advanced human HCC. Analyses of the leading edge genes revealed that most of them are involved in mRNA transcription (*SND1, BTF3, MED30, EXOSC3*), rRNA processing (*EXOSC3, NAS2*), protein translation and folding (*RPSs, RPLs, EIF3, EEF1, CCT2, CCT6A, CCT8*), cell cycle regulation (*CAPRIN1, GNB2L1, CGREF1, DTYMK, PCNP*) and mitochondrial function (*SND1, CHCHD3, PDSS, SLC25A39*) ([supplementary material Table S5](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010462/-/DC1)).

###### 

Comparison of *Myc*-induced zebrafish liver tumors with different stages of human hepatocarcinogenesis using gene set enrichmentanalysis.

![](DMM010462T3)

A 16-gene signature can be used to classify advanced stages of HCC
------------------------------------------------------------------

Myc is a global transcription factor, therefore it is interesting to examine the Myc target genes involved in hepatocarcinogenesis. Thus, the upregulated genes from the *Myc*-induced zebrafish liver tumors were compared with Myc target genes retrieved from the Molecular Signatures Database (MSigDB) ([@b41-0060414]), where 382 Myc targeted genes could be mapped by the zebrafish transcripts in the RefSeq database. We found that 16 of them presented in the 125 upregulated genes from the Myc-induced zebrafish tumors, including genes encoding ribosomal proteins (*RPL13A*, *RPL19*, *RPL22*, *RPS2*, *RPS11*, *RPS28*), mitochondria (*FPGS, SLC7A3, ALDOA*), translation (*PABPC4, ANKHD1*), cell cycle inhibition (*DUSP1, CGREF1*), glycogen biosynthesis (*PPP1R3C*), transcription factor (*TEF*) and a member of the arrestin family (*ARRDC3*). Notably, *DUSP1* and *ARRDC3* have been suggested as tumor suppressors ([@b2-0060414]; [@b4-0060414]). We also performed gene set enrichment analysis (GSEA) using these 16 genes as *Myc* signature to classify different mouse HCC models and various stages of human HCCs ([Fig. 5B](#f5-0060414){ref-type="fig"}; [Table 3](#t3-0060414){ref-type="table"}). The 16-gene signature showed a better prediction of Myc transgenic mice ([Fig. 5A](#f5-0060414){ref-type="fig"}). Interestingly, these 16 genes also clearly distinguish HCC with less severe human liver tumors, with better correlation to more advanced HCC ([Fig. 5B](#f5-0060414){ref-type="fig"}; [Table 2](#t2-0060414){ref-type="table"}). Therefore, the 16-gene signature could potentially be used as a molecular prognosis signature for human HCC patients.

Similarly, we also compared the 125 upregulated genes from our data with another set of Myc target genes ([@b45-0060414]) (<http://www.myc-cancer-gene.org/index.asp>), whereby 681 genes were identified with zebrafish homologs and 24 of them were overlapped (indicated by asterisks in [supplementary material Table S2](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010462/-/DC1)), including five genes (*RPL13A*, *RPL19*, *RPL22*, *RPS11* and *FPGS*) in the earlier-identified 16-gene list. We found that the 24 genes also showed a better prediction of Myc transgenic mice ([supplementary material Table S4](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010462/-/DC1)) and high correlation with advanced and very advance HCC ([supplementary material Table S5](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.010462/-/DC1)) as compared with the entire upregulated gene list.

DISCUSSION
==========

By generating a transgenic zebrafish model and utilizing RNA-sequencing technology, we have examined the transcriptome of zebrafish liver tumors driven by the oncogene *Myc*. Our analyses have shown that ribosome biogenesis constitutes the key features of *Myc*-mediated liver tumors. Cross-species analyses showed that the zebrafish *Myc* model correlated well with *Myc* transgenic mouse models for liver cancer. We also illustrated that the *Myc*-induced zebrafish liver tumors possessed molecular signatures common to human HCC. Interestingly, a small set of 16 Myc target genes was identified that could be further tested as HCC prognosis markers in clinical samples.

Consistent with previous reports that MYC is the key regulator of ribosome gene expression and protein translation ([@b42-0060414]), we observed that essentially all ribosomal protein genes as well as several translation factor genes were upregulated. The ribosome is the machinery for protein synthesis; therefore, upregulation of ribosome gene expression could reflect the requirement for increased cell proliferation. This is in contrast to our two other liver tumor models induced by overexpression of *kras^v12^* or *xmrk* in transgenic zebrafish ([@b23-0060414]; [@b29-0060414]; [@b30-0060414]), which also showed prominent cell proliferation and liver overgrowth but did not show such obvious upregulation of ribosome genes (data not shown). Thus, the upregulation of ribosome genes in the *Myc* transgenic zebrafish model should be a specific event elicited by the Myc pathway and thus suggests extra-ribosomal functions for these ribosomal proteins. Extra-ribosomal functions have been found in both prokaryotes and eukaryotes and include regulation of their own transcription and translation, DNA repair endonuclease activity and modulation of gene-specific transcription and translation, such as sequestering MDM, protecting p53 and sequestering their activator Myc ([@b25-0060414]; [@b36-0060414]). Consistent with these reports, we observed obvious upregulation of *rpl11*, which can bind to Myc and inhibit its function. In addition, *rpl26* and *rps7*, whose homologs have been shown to inhibit MDM2 and to protect p53, were also upregulated. Moreover, among the significantly upregulated ribosome genes, *rpl12*, *rpl13*, *rpl36a* and *rps8* have also been reported to be upregulated in human HCC ([@b16-0060414]).

Although liver tumorigenesis progressed with time in the *TO(Myc)* line, we observed mostly hepatocellular adenoma after 4 months of treatment, despite the fact that the same mouse *Myc* gene expressed in lymphocytes causes leukemia in transgenic zebrafish ([@b20-0060414]; [@b19-0060414]). By contrast, transgenic expression of *kras^v12^* or *xmrk* alone is sufficient to induce HCC in transgenic zebrafish ([@b23-0060414]; [@b29-0060414]; [@b30-0060414]), suggesting that these oncogenes function distinctively in different tissues and possess different potencies to drive liver tumorigenesis. Similar to our model, Sawey et al. reported that an embryonic hepatoblast cell line lacking *P53* and overexpressing *Myc* was not tumorigenic *in vivo* in the mouse model. By introducing other mutations or transgenes, these cells provide a sensitized background where a single additional oncogenic factor can trigger tumorigenesis ([@b39-0060414]). In contrast to the histopathological diagnosis, our comparative transcriptomic analyses showed that the *Myc*-induced zebrafish liver tumors captured the molecular signatures of advanced HCCs, suggesting that upregulation of *Myc* signatures are often correlated with malignancy status. In accordance with this speculation, a global gene expression analysis showed that the activation of the *MYC* transcription signature was strongly associated with malignant conversion of liver cancer ([@b6-0060414]; [@b14-0060414]; [@b15-0060414]; [@b40-0060414]). Thus, our *TO(Myc)* line could serve as a good driving line for hepatocarcinogenesis. Upregulated Myc can affect multiple hallmark capabilities, such as proliferative signaling, energy metabolism, angiogenesis, invasion and survival ([@b9-0060414]). By crossing the *Myc* transgenic line with other transgenic or mutant lines, the progress of hepatocarcinogenesis could be accelerated, as we observed in a *p53^−/−^* background (our unpublished data). It could also provide a sensitized background in which a single additional deregulated oncogene can trigger tumorigenesis, thus enabling new oncogenes to be uncovered and studied in the economical and potentially high-throughput zebrafish model. Recently, myc transgenic medaka with liver hyperplasia have also been reported ([@b27-0060414]) and consistent observations were produced from the two complementing transgenic fish models. It is also interesting to note that Myc-induced mouse HCCs could be rapidly regressed after inactivation of Myc expression ([@b5-0060414]; [@b14-0060414]; [@b40-0060414]). We also observed a rapid liver tumor regression from our *TO(Myc)* transgenic zebrafish after removal of Dox (data not shown), similar to earlier reported liver tumor regression from our *TO(xmrk)* transgenic zebrafish ([@b23-0060414]).

MATERIALS AND METHODS
=====================

Generation of Tg(fabp10:TA; TRE:Myc; krt4:GFP) zebrafish
--------------------------------------------------------

Zebrafish were maintained in compliance with Institutional Animal Care and Use Committee (IACUC) guidelines. Transgenic founders (F0) were generated by co-injection into one-cell stage embryos of three plasmid constructs: pFABP10-rtTA2s-M2 \[a 2-kb zebrafish *fabp10* promoter ([@b10-0060414]) in prtTA2s-M2 (ClonTech)\], pTRE-Myc \[full-length mouse *Myc* cDNA in pTRE2 (ClonTech)\] and pKRT4-GFP ([@b8-0060414]) (GFP marker for transgenic screening). Injected embryos were raised to adulthood and F0 founders were crossed with wild-type fish for transgenic screening. PCR was conducted on GFP-positive embryos to confirm the co-segregation of these three plasmids. A positive F0 fish was used to establish a stable *Tg(fabp10:TA; TRE:Myc; krt4:GFP)* transgenic line, known as *TO(Myc)*. We always observed a co-segregation of the three plasmids and standard Mendelian inheritance ratios for a single transgenic locus in subsequent generations.

Doxycycline induction and histology analysis
--------------------------------------------

Dox treatment was conducted in six-well plates for embryos and in 6-l tanks for juveniles and adults, with different concentrations of Dox (Sigma-Aldrich). Water was changed every other day. Fish density was ∼60 juveniles or ∼25 adults per tank. Fish samples were fixed in either Bouin\'s fixative or formalin solution (Sigma-Aldrich). Sections (5 μm) were processed using the Reichert-Jung 2030 BIOCUT Microtome and stained with Mayer\'s H&E.

RNA sample preparation and SAGE library sequencing
--------------------------------------------------

Liver tumors (M+D+) and three non-tumor control livers (M-D-, M-D+ and M-D+) were prepared for RNA extraction. Four to five livers were pooled for each RNA extraction. Total RNA was extracted using TRIzol Reagent (Invitrogen) and treated with DNase I (Invitrogen) to remove genomic DNA contamination. Total RNA samples were then submitted to Mission Biotech, Taiwan, for SOLiD-based SAGE sequencing. Briefly, mRNA was purified using Dynabeads Oligo(dT) EcoP (Invitrogen) and subjected to cDNA synthesis. Resultant cDNA was digested by *Nla*III and then sequencing adapters were added to the cDNA fragments.

Sequence tag mapping and annotation
-----------------------------------

The tags were mapped to the zebrafish Reference Sequence database with a criterion of allowing maximum two nucleotide mismatches. Uniquely mapped tag counts for each transcript were normalized to TPM to facilitate comparison between different samples. To eliminate transcripts with only marginal expression, the expression level of the transcripts had to be above 10 TPM in at least one group of samples (control or treated) in order to be included in subsequent bioinformatics analyses. Because sequence tags for vitellogenins were highly variable in different samples, these vitellogenin tags were excluded in all subsequent transcriptomic analyses. To facilitate functional implications of zebrafish transcriptome, all zebrafish genes were mapped to annotated human and mouse genes in order to use existing online software developed for human genes. Thus, Unigene annotation of zebrafish transcript entries were retrieved from the UniGene database and human and mouse homology mapping of zebrafish Unigene clusters were retrieved from the HomoloGene database. For Unigene clusters mapped by more than one transcript entries, the highest TPM value was used to represent the expression level of the Unigene cluster ([@b43-0060414]). Functional characterization of Unigene clusters was based on Gene Ontology classification and can be obtained from Stanford\'s SOURCE database ([@b3-0060414]).

Bioinformatic analyses
----------------------

Gene ontology enrichment analysis was performed using DAVID (Database for Annotation, Visualization and Integrated Discovery) ([@b12-0060414]) with the total zebrafish genome information as the background and *P*-values representing a modified Fisher\'s exact *t*-test. Gene Ontology Fat categories were used for this analysis. The cutoff for *P*-values was 0.01. We used GSEA to establish the relatedness between zebrafish and mammalian liver cancers ([@b41-0060414]). Mammalian liver cancer transcriptome data were retrieved from the Gene Expression Omnibus (GEO) database. These data include different stages of human HCCs (GSE12443, GSE6764), human HCAs (GSE11819, GSE7473) and several mouse HCC models (GSE1897) ([@b15-0060414]; [@b21-0060414]; [@b34-0060414]; [@b33-0060414]; [@b44-0060414]). The statistical significance of the normalized enrichment score (NES) was estimated by using an empirical phenotype-based permutation test procedure. A false discovery rate (FDR) value was provided by introducing adjustment of multiple hypothesis testing.
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The RNA sequencing data reported in this study have been submitted to the Gene Expression Omnibus with access number GSE40745.
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